首页 | 本学科首页   官方微博 | 高级检索  
     

Studies on the Effects of the Immunosuppressant FK—506 on the High—risk Corneal Graft Rejection
引用本文:Minhua Wang,Yuesheng Lin,Jiaqi Chen,Yongming Liu,Hanping Xie,Chengtian YeZhongshan Ophthalmic Center,Sun Yat-sen University,Guangzhou 510060,China. Studies on the Effects of the Immunosuppressant FK—506 on the High—risk Corneal Graft Rejection[J]. 眼科学报, 2002, 18(3): 160-164
作者姓名:Minhua Wang  Yuesheng Lin  Jiaqi Chen  Yongming Liu  Hanping Xie  Chengtian YeZhongshan Ophthalmic Center  Sun Yat-sen University  Guangzhou 510060  China
作者单位:Minhua Wang,Yuesheng Lin,Jiaqi Chen,Yongming Liu,Hanping Xie,Chengtian YeZhongshan Ophthalmic Center,Sun Yat-sen University,Guangzhou 510060,China
摘    要:Purpose: To evaluate the clinical efficacy of FK-506 on suppressing high-risk cornea transplantation rejection.Methods: In a randomized controlled clinical trial, 56 eyes of 56 patients with high-risk keratoplasty (including total corneal transplantation TCT, total corneal transplantation with circular lamellar sclera CST, vascularization corneal transplantation and corneal retransplantation) were divided into the experimental group and the control group (each with 28 eyes). The experimental group was treated by FK-506 eyedrops (0. 5 mg/ml) and TobraDex eyedrops, compared with the control group that was treated by 1% CsA eyedrops and TobraDex eyedrops. In the average 8. 1-month follow-up period, the visual acuity, graft transparent duration and Rejection Index (RI) of grafts were observed. Results: In the follow-up period, the graft rejection rate of the experimental and the control group was 63. 6% and 95. 2% respectively (x2 =4. 72, P<0. 05) with significant difference.Conclusions: The local applicati

关 键 词:高风险角膜移植排斥  免疫抑制剂  FK-506  滴眼药物

Studies on the Effects of the Immunosuppressant FK-506 on the High-risk Corneal Graft Rejection
Minhua Wang,Yuesheng Lin,Jiaqi Chen,Yongming Liu,Hanping Xie,Chengtian Ye. Studies on the Effects of the Immunosuppressant FK-506 on the High-risk Corneal Graft Rejection[J]. Eye science, 2002, 18(3): 160-164
Authors:Minhua Wang  Yuesheng Lin  Jiaqi Chen  Yongming Liu  Hanping Xie  Chengtian Ye
Affiliation:Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China
Abstract:Purpose: To evaluate the clinical efficacy of FK-506 on suppressing high-risk cornea transplantation rejection.Methods: In a randomized controlled clinical trial, 56 eyes of 56 patients with high-risk keratoplasty (including total corneal transplantation TCT, total corneal transplantation with circular lamellar sclera CST, vascularization corneal transplantation and corneal retransplantation) were divided into the experimental group and the control group (each with 28 eyes). The experimental group was treated by FK-506 eyedrops (0. 5 mg/ml) and TobraDex eyedrops, compared with the control group that was treated by 1% CsA eyedrops and TobraDex eyedrops. In the average 8. 1-month follow-up period, the visual acuity, graft transparent duration and Rejection Index (RI) of grafts were observed. Results: In the follow-up period, the graft rejection rate of the experimental and the control group was 63. 6% and 95. 2% respectively (x2 =4. 72, P<0. 05) with significant difference.Conclusions: The local application of FK-506 suppressed effectively the graft rejection of corneal transplantation of the patients at high risk. Eye Science 2002; 18: 160 - 164.
Keywords:cornea transplantation   graft rejection   eye drops   FK-506
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号